Trial · NCT03172624
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
NCT03172624, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2025-12-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer. Trials, record NCT03172624. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03172624
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
- NCT number
- NCT03172624
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 64 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Salivary Gland Cancer
- Interventions
- Nivolumab, Ipilimumab
- First posted
- 2017-06-01
- Last updated
- 2025-12-18
- Results first posted
- 2025-12-18
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Best Overall Response Rate | 2 years | using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Best Overall Response Rate | 2 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Best Overall Response Rate | R/M Adenoid Cystic Carcinoma (ACC) | Partial Response | 2 | Participants | |
| Best Overall Response Rate | R/M SGC of Any Histology, Except ACC (Non ACC) | Partial Response | 5 | Participants | |
| Best Overall Response Rate | R/M Adenoid Cystic Carcinoma (ACC) | Stable Disease | 17 | Participants | |
| Best Overall Response Rate | R/M SGC of Any Histology, Except ACC (Non ACC) | Stable Disease | 8 | Participants | |
| Best Overall Response Rate | R/M Adenoid Cystic Carcinoma (ACC) | Progressive Disease | 13 | Participants | |
| Best Overall Response Rate | R/M SGC of Any Histology, Except ACC (Non ACC) | Progressive Disease | 18 | Participants | |
| Best Overall Response Rate | R/M Adenoid Cystic Carcinoma (ACC) | Not Evaluable | 0 | Participants | |
| Best Overall Response Rate | R/M SGC of Any Histology, Except ACC (Non ACC) | Not Evaluable | 1 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | R/M Adenoid Cystic Carcinoma (ACC) | 32 | |
| Overall Study | STARTED | R/M SGC of Any Histology, Except ACC (Non ACC) | 32 | |
| Overall Study | COMPLETED | R/M Adenoid Cystic Carcinoma (ACC) | 32 | |
| Overall Study | COMPLETED | R/M SGC of Any Histology, Except ACC (Non ACC) | 32 | |
| Overall Study | NOT COMPLETED | R/M Adenoid Cystic Carcinoma (ACC) | 0 | |
| Overall Study | NOT COMPLETED | R/M SGC of Any Histology, Except ACC (Non ACC) | 0 |
Source ClinicalTrials.gov
Adverse events114
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Investigations | R/M Adenoid Cystic Carcinoma (ACC) | 2 | 32 | |
| other | Alanine aminotransferase increased | Investigations | R/M SGC of Any Histology, Except ACC (Non ACC) | 0 | 32 | |
| other | Anemia | Blood and lymphatic system disorders | R/M Adenoid Cystic Carcinoma (ACC) | 4 | 32 | |
| other | Anemia | Blood and lymphatic system disorders | R/M SGC of Any Histology, Except ACC (Non ACC) | 1 | 32 | |
| other | Aspartate aminotransferase increased | Investigations | R/M Adenoid Cystic Carcinoma (ACC) | 4 | 32 | |
| other | Aspartate aminotransferase increased | Investigations | R/M SGC of Any Histology, Except ACC (Non ACC) | 2 | 32 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | R/M Adenoid Cystic Carcinoma (ACC) | 0 | 32 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | R/M SGC of Any Histology, Except ACC (Non ACC) | 4 | 32 | |
| other | Hyponatremia | Metabolism and nutrition disorders | R/M Adenoid Cystic Carcinoma (ACC) | 4 | 32 | |
| other | Hyponatremia | Metabolism and nutrition disorders | R/M SGC of Any Histology, Except ACC (Non ACC) | 5 | 32 |
1 to 10 of 114Source ClinicalTrials.gov
See all 114 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | R/M Adenoid Cystic Carcinoma (ACC) | 6 | 32 |
| Total, all-cause mortality | R/M SGC of Any Histology, Except ACC (Non ACC) | 7 | 32 |
| Total, other adverse events | R/M Adenoid Cystic Carcinoma (ACC) | 11 | 32 |
| Total, other adverse events | R/M SGC of Any Histology, Except ACC (Non ACC) | 14 | 32 |
| Total, serious adverse events | R/M Adenoid Cystic Carcinoma (ACC) | 18 | 32 |
| Total, serious adverse events | R/M SGC of Any Histology, Except ACC (Non ACC) | 9 | 32 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| R/M Adenoid Cystic Carcinoma (ACC) vs R/M SGC of Any Histology, Except ACC (Non ACC): deaths from any cause | Trial comparisons |
| R/M Adenoid Cystic Carcinoma (ACC) vs R/M SGC of Any Histology, Except ACC (Non ACC): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03172624
GET https://conductscience.org/api/trials/v1/NCT03172624/events?page=2